Karuna Therapeutics Inc expected to post a loss of $2.25 a share - Earnings Preview

Karuna Therapeutics

20/02/2023 19:05

* Karuna Therapeutics Inc  KRTX.OQ   KRTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
22 (estimated). 
    * The Boston Massachusetts-based  company is expected to
report
revenue of $5.88 thousand, according to the mean estimate from
17 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Karuna Therapeutics
Inc
is for a loss of $2.25 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 20 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Karuna
Therapeutics Inc is $283.5​, above​ its last closing price
of $197.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -2.13       -2.13      -2.38     Missed  -11.5
 Jun. 30 2022  -2.04       -2.09      -2.17     Missed  -3.6
 Mar. 31 2022  -2.18       -2.11      -1.95     Beat    7.6​
 Dec. 31 2021  -1.66       -1.73      -0.94     Beat    45.8
 ​​Sep.        -1.45       -1.44      -1.72     Missed  -19.4
 30 2021                                                
 Jun. 30 2021  -1.30       -1.34      -1.17     Beat    12.5​
 Mar. 31 2021  -1.16       -1.13      -1.07     Beat    5.4
 Dec. 31 2020  -0.90       -0.90      -0.89     Beat    0.6
 This summary was machine generated February 20 at 19:05 GMT. 
All figures in US dollars  unless otherwise stated